Introduction: Patients with Crohn's disease have poorer health-related quality of life [HRQoL] than healthy individuals, even when in remission. Although HRQoL improves in patients who achieve drug-induced or surgically induced remission, the effects of surgery overall have not been well characterised. Methods: In a randomised trial, patients undergoing intestinal resection of all macroscopically diseased bowel were treated with postoperative drug therapy to prevent disease recurrence. All patients were followed prospectively for 18 months. Results: A total of 174 patients were included. HRQoL was poor preoperatively but improved significantly [p < 0.001] at 6 months postoperatively. This improvement was sustained at 18 months. Females and smokers had a poorer HRQoL when compared with males and non-smokers, respectively. Persistent endoscopic remission, intensification of drug treatment at 6 months, and anti-tumour necrosis factor therapy were not associated with HRQoL outcomes different from those when these factors were not present. There was a significant inverse correlation between CDAI, [but not endoscopic recurrence, CRP, or FC] on HRQoL.
Introduction
'Quality of life' is an important part of clinical evaluation. Healthrelated quality of life [HRQoL] is a global measure of the patient's perceptions, illness experience, and functional status, and incorporates social, cultural, psychological, and disease-related factors. 1 Crohn's disease is an incurable inflammatory bowel disease [IBD] characterised by a chronic, relapsing course. Its relatively young age of onset, associated morbidity, disability, debilitating symptoms, and sometimes disfiguring complications have the potential to cause significant psychosocial stress.
Symptoms of active Crohn's disease such as diarrhoea, abdominal pain, and gastrointestinal bleeding, have been shown in large multinational questionnaire-based studies to have a substantial impact on HRQoL. [2] [3] [4] [5] It is widely accepted that deterioration in HRQoL and high levels of emotional distress can be observed in patients with active disease. 6, 7 However even in the absence of active disease, patients with Crohn's disease report worse HRQoL than those without. [8] [9] [10] [11] Achievement of disease remission, whether by drug therapies [corticosteroids, immunomodulators and/or biologicals] or surgery, is associated with an improvement in HRQoL. [12] [13] [14] [15] [16] [17] [18] [19] Even in the era of frequent immunomodulator use, including biologicals, patients with Crohn's disease commonly require surgery. 20 HRQoL in patients being referred for surgery is poor 18 but does improve following resectional surgery. 19, 21, 22 Ileo-caecal resection, both open and laparoscopic, is associated with significant short-term improvements in HRQoL. 18, [23] [24] [25] However, the long-term durability of improved HRQoL following surgery in these patients is contentious. 19, [26] [27] [28] High rates of clinical and endoscopic recurrence have been shown to affect adversely HRQoL postoperatively in patients with Crohn's disease. 26, 27 Recurrent disease, smoking, personality factors, including coping behaviours, and body image disturbance all appear to affect HRQoL after surgery. 25, 27, [29] [30] [31] Whether elective surgery with resection for Crohn's disease is superior to drug therapy in the biologicals era in terms of symptom control, quality of life, and health economic analysis, is not known. Results from the LYR!C-Trial, 32 a randomised controlled trial comparing infliximab treatment with laparoscopic ileo-colic resection in patients with recurrent Crohn's disease of the distal ileum, with respect to quality of life and costs, are not yet available.
Prospective studies to date evaluating HRQoL postoperatively in patients with Crohn's disease have been small. Whereas most show some improvement in HRQoL, this is not a consistent finding across the literature. 18, 19, 26, 27 The effects of strategic prophylactic postoperative drug treatment regimens in improving HRQoL have not been investigated.
This study aimed to determine the changes in HRQoL following intestinal resection of all macroscopic Crohn's disease in patients treated with selective postoperative immunosuppressive therapy as prophylaxis against disease recurrence. We aimed to determine whether there are specific patient and disease factors or management strategies that can influence HRQoL outcome in this population.
Methods

The clinical postoperative recurrence study
The POCER study was a prospective randomised trial that aimed to assess the value of postoperative endoscopic assessment and treatment step-up for early mucosal recurrence. Patients were stratified according to risk of recurrence. Smokers, patients with perforating disease, or patients with ≥ 1 previous resections were classified as at 'high-risk' of recurrence; all others were deemed 'low-risk'. All patients underwent resection of all macroscopic disease and then received 3 months of oral metronidazole therapy. High-risk patients also received daily thiopurine in standard dose or adalimumab therapy if thiopurine-intolerant. Low-risk patients received no further medication.
Patients were randomly assigned at study recruitment in a 2:1 ratio to colonoscopy at 6 months [active care] or no colonoscopy [standard care]. The study group allocation sequence was computergenerated with block randomisation undertaken for each centre in blocks of 3 in a 2:1 ratio [2 active care:1 standard care]. Participants were randomised by a computer-generated list maintained centrally. Data analysis was undertaken by statisticians who were not involved in the clinical study and who were blinded to the study groups.
For endoscopic recurrence [Rutgeerts score ≥ i2] at 6 months [active care arm only], patients stepped-up to thiopurine, fortnightly adalimumab with thiopurine, or weekly adalimumab. The primary end-point was endoscopic recurrence at 18 months. Endoscopic remission was defined as Rutgeert's score i0 or i1 [i0 = no lesions, i1 = mild small superficial anastomotic lesions], and recurrence defined as i2, i3 or i4 [moderate to severe lesions].
All patients provided written informed consent before inclusion in the study. Ethical approval for the study was obtained from the human research ethics committees of the participating hospitals [Clinical Trial Registration: NCT00989560].
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Variables and measures
The general Short-Form 36 [SF36] 33 and disease-specific Inflammatory Bowel Disease Questionnaire [IBDQ] 34 were used to measure the dependent variable HRQoL. The SF36 is a general, validated, outcome measure which attempts to capture aspects of health that are important to all people. 33 Its use is well established for a wide variety of disease states. [35] [36] [37] [38] The self-questionnaire contains 36 questions subdivided into eight dimensions each of which corresponds to a different aspect of health. Responses are recorded, summed, and transformed to provide the eight dimensions with scores between 0 and 100, with higher scores indicating better health. 33 Scores from the eight dimensions can be aggregated into two summary measures: the Physical [PCS] and Mental [MCS] Component Summary scores [ Table 1 ], also scored from 0 to 100, with higher scores representing better HRQoL. 39 The Australian Bureau of Statistics average SF36 score for each of the eight dimensions is 75-90 in adults without illness, depending on gender, age, income, and smoking status. 40 For individual dimensions of the SF36, a change of 5 or more points is considered to be a minimum important difference. 41 The IBDQ is the most widely used HRQOL instrument for patients with IBD. The validity, reliability, and responsiveness of the IBDQ have previously been established. 34, 42 The scale has 32 items scored on a 7-point Likert scale, ranging from 1, [worst health] to 7 [best health]. 34 Only the IBDQ total scores were used with a score range of 32 to 224, with higher scores reflecting better HRQOL. 34 A total IBDQ score of ≥ 170 is associated with clinical remission. 43, 44 The mean IBDQ for Australian patients with Crohn's disease is 155.6 as previously reported by Gibson et al. 45 A change of 16 or more points is considered clinically meaningful. 43 Patients were asked to complete questionnaires for both the SF36 and IBDQ preoperatively [baseline] and at 6, 12, and 18 months following surgery. In patients who had a diverting ileostomy created at the time of intestinal resection, reversal of the stoma and restoration of the normal faecal stream was considered the index surgery, with postoperative HRQoL assessment performed from this time.
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Statistical analysis
Comparisons between groups were performed using either KruskallWallis or ANOVA [analysis of variance] tests for continuous data and either chi squared or Fisher's exact test for categorical data, as appropriate. Associations between HRQoL and all possible predictors were assessed with analysis of covariance or linear regression. Variables that were found to be associated with quality of life in a univariate analysis were entered into a multivariate regression. Correlation between responses to IBDQ and SF36 questionnaires and clinical and biochemical data were assessed using Spearman's correlation. To enhance statistical power, mean PCS and MCS scores, rather than the individual dimension scores, were used for this analysis. In order to maintain the overall level of significance for the study at 0.05 levels, Bonferroni adjustment was used for individual tests.
Results were expressed as mean and standard deviation [SD] so as to be consistent with the published literature. The distribution of results was approaching normality.
Results
A total of 174 patients were included at 17 hospitals in Australia and New Zealand, and completed follow up to 18 months postoperatively. Of 122 patients randomised to endoscopic intervention [6 month colonoscopy], 101 were high-risk, compared with 44 of 56 in the standard care arm [ Figure 1 ]. Demographic details are shown in Table 2 . All patients underwent intestinal resection of all macroscopic disease.
Of the 56 patients who withdrew before 18 months [ Figure 1 11 were related to comorbidity, 9 to loss to follow-up, 8 to protocol violation, 3 to patient preference, and 3 to pregnancy. An additional 10 patients, who remained enrolled in the study for the duration of the 18 months of follow-up, elected not to complete the quality of life questionnaires at the intervals stipulated in the study design and therefore quality of life data were not available for these patients. There were no differences between patients who did or did not complete the 18-month follow-up with respect to age, sex, smoking status, or other baseline parameters.
Indications for surgery included symptomatic luminal Crohn's disease refractory to standard medical therapy, intestinal obstruction from inflammatory or fibrostenotic disease, or penetrating complications of Crohn's disease, such as abscess formation [ Table 2 ].
A total of 133 patients underwent ileo-caecal resection, 15 simultaneous ileo-caecal and proximal small intestinal resection, 12 ileal resection, 8 subtotal colectomy, and 6 simultaneous ileo-caecal and 46 In short, a structured programme to prevent postoperative recurrence, with colonoscopic assessment at 6 months and treatment intensification for endoscopic disease recurrence, was significantly superior to optimal drug therapy alone in preventing recurrence at 18 months.
Quality of life before and after surgery
HRQoL was poor preoperatively when measured by the PCS and MCS scores and the IBDQ [40, 44, Figure 3A and B]. When measured by the IBDQ, statistically significant differences were seen between males and females at 6 and 12 months [p = 0.007 and p = 0.006, respectively] [ Figure 3C ].
Smoking
Smokers had a lower HRQoL compared with non-smokers. Differences reached statistical significance postoperatively for PCS HRQoL, health-related quality of life. 
Disease duration
Disease duration did not appear to affect HRQoL in our population. There were no statistically significant differences in HRQoL pre-or postoperatively when measured by SF36 of IBDQ between those with a disease duration > 10 years when compared with those with a disease duration of ≤ 10 years.
Perianal disease
Perianal disease was present in 12% of patients preoperatively and in 11% postoperatively. Both preoperatively and postoperatively, HRQoL did not appear to be affected by the presence of perianal disease, with no statistically significant differences seen in the PCS, MCS, or IBDQ scores between those with and without perianal disease.
CDAI
There was a significant inverse relationship between CDAI and HRQoL when measured by both the SF-36 and IBDQ. Statistically significant differences in the PCS, MCS, and IBDQ scores were seen Figure 3C shows scores for the IBDQ with respect to gender.
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Faecal calprotectin
There were no statistically significant differences in quality of life between those with a FC < 100 µg vs FC ≥ 100 µg when measured by the SF36 or IBDQ.
Active care arm
There were no significant differences seen in HRQoL between patients in the active care arm of the POCER study, when compared with those in the standard care arm when measured by SF36 and IBDQ, both pre-and postoperatively. 
Endoscopic remission
Adalimumab therapy
Patients who received adalimumab therapy postoperatively did not have a different HRQoL compared with those who did not at 6, 12, or 18 months. 
Surgical technique
Correlation analysis
The PCS and MCS scores both correlated significantly with the IBDQ. CDAI correlated significantly with the IBDQ total score [r = -0.5046, p = 0.0049]. There was no correlation seen between Rutgeerts endoscopic score, CRP, or FC and quality of life measures. 59 [20] 45 [13] 26 [13] <0.001
75 [15] 46 [20] 34 [15] <0.001
78 [15] 51 [18] 39 [20] <0.001
MCS [0-100]
63 [21] 50 [16] 31 [15] <0.001
75 [15] 51 [19] 38 [14] <0.001
76 [16] 51 [24] 40 [20] <0.001
IBDQ [32-224]
154 [35] 138 [27] 101 [23] <0.001 183 [24] 134 [29] 118 [19] <0.001 185 [26] 143 [23] 124 [32] <0.001
HRQoL, health-related quality of life; CDAI, Crohn's Disease Activity Index.
Discussion
Numerous physical and psychological factors contribute to the poor HRQoL in patients with Crohn's disease. Long-term drug treatment and the need for surgery have measurable effects on both individual patients and society. Collection of HRQoL data provides insight into the impact of treatment on patient health status and well-being. Of the 80% of patients with Crohn's disease who will require bowel surgery at some time in their life, up to 70% will require a second operation. 47 Prior to the routine use of immunomodulators and biologicals for moderate to severe Crohn's disease, surgery was used early and frequently as part of disease management and was efficacious in terms of symptom relief, and successful restoration of 90% of patients to good or excellent health. 48 Even in the era of routine immunosuppressive therapy for moderate to severe Crohn's disease, the need for surgery remains high. 20 HRQoL in patients being referred for surgery is poor 18 but improves following resectional surgery. 19, 21, 22 However, these improvements may not be durable, mainly because of the high rates of clinical and endoscopic recurrence which have been shown to adversely affect HRQoL postoperatively in some studies. 26, 27 Small studies have found that there may be a sustained improvement in HRQoL after surgery. Thirlby and colleagues, 19 in their study of 56 Crohn's disease patients having resectional surgery, demonstrated durable improvement in postoperative quality of life when compared with their preoperative status after a mean of 16 The durability of any improvement in HRQoL following intestinal resection has not been examined in a population receiving prophylactic drug therapy and rigorous postoperative monitoring. The strategic approach, with a focus on maintaining remission, in our study was associated with significant and sustained improvements in general and disease-specific HRQoL. Of the many patient, disease, and treatment factors examined, only gender, smoking status, and CDAI were associated with consistent differences in postoperative HRQoL.
There was no difference in HRQoL in patients in the standard vs active care groups, despite the differences in endoscopic recurrence rates at 18 months. 46 This is likely to be a reflection of the absence of a significant difference in clinical recurrence [CDAI > 150] rates between the active and standard care groups at 18 months and the fact that CDAI does not correlate with endoscopic recurrence after ileo-colonic resection. 46 It is possible that, with extended follow-up, differences between the two groups would emerge as patients with endoscopic recurrence become symptomatic.
Elevated CRP postoperatively was not found to be reliably or persistently associated with poor HRQoL. This result is likely to reflect both the poor performance of CRP as an indicator of clinically or endoscopically active Crohn's disease 49 and the largely subjective nature of quality of life questionnaires.
The significantly lower PCS score preoperatively, and lower PCS, MCS, and IBDQ scores postoperatively, in female patients when compared with males may reflect the partly lower quality of life reported in healthy female and female IBD populations. [50] [51] [52] [53] [54] [55] Specific female concerns regarding interpersonal relationships and sexual comfort, behavior, and functioning may play a role but this requires further investigation. The association of psychiatric comorbidity and stress with HRQoL in patients with IBD is well established. [56] [57] [58] [59] Depressive disorders and anxiety are more common in women than men and this is likely to be a significant factor in determining HRQoL in patients with and without IBD. 60, 61 In this study smoking was associated with a lower HRQoL postoperatively. Smoking has been consistently reported across the literature as being associated with aggressive disease, poor outcomes and higher rates of surgical therapy in Crohn's disease. [62] [63] [64] Smoking also appears to be associated with lower QoL scores in patients with Crohn's disease. 51, 53, 54, 65 In the POCER study smoking was associated with a significant increase in the risk of endoscopic recurrence [OR 2·4, 95%CI 1·2-4·8, p=0·02] confirming a more aggressive disease phenotype in these patients. 46 However endoscopic recurrence was not associated with a worse HRQoL in this study indicating that non-disease factors may be responsible for the lower quality of life reported by smokers in this study.
A higher clinical disease activity index, but not direct measures of active disease, such as CRP, FC, or endoscopic recurrence, was associated with a lower HRQoL. This suggests that symptoms, which are directly measured in the CDAI, reflect subjective personal factors and not active mucosal disease or drug effects. Further questions reflecting bowel symptoms and general wellbeing, which form part of the CDAI, are also part of the IBDQ; a close correlation between the CDAI and quality of life measures is therefore expected.
Comparing the magnitude of benefit in quality of life following resectional surgery to other interventions is difficult as there are no direct comparative studies. However we can examine the effect of anti-TNF therapies and small molecules on quality of life Crohn's disease as described in the pivotal trials of these drugs and compare the changes in quality of life to those we observed in our postoperative cohort. Targan et al 66 69 At 26 weeks there was a mean change in IBDQ from baseline of 31.4, 39.9 and 45.2 for the three groups respectively. Vedolizumab, an α4β7 integrin antagonist, has been shown to induce remission by 6 weeks in more patients compared to placebo. 70 There was no clear improvement however in the IBDQ-measured QoL with maintenance vedolizumab therapy [whether given every 4 or 8 weeks].
The magnitude if improvements in HRQoL seen with both infliximab, adalimumab and combination infliximab and azathioprine are similar to what we have observed postoperatively in this study where an increase in IBDQ of 46 points was seen at 6 months postoperatively when compared to baseline.
In conclusion, this study has shown that intestinal resection of all macroscopic Crohn's disease followed by prophylactic drug therapy with a focus on maintaining remission, is associated with significant and durable improvement in general and disease-specific HRQoL. This improvement is sustained at 18 months post operatively, irrespective of endoscopic recurrence or the type of drug therapy. Women and smokers appear to have lower quality of life, despite removal of all active disease, suggesting that non-disease factors should receive attention in these patients.
Conflict of interest statement
EK Wright, KJ Ritchie, EO Krejany, A Gorelik, L Prideaux, TH Florin, H Debinski, I Kronborg, MJ Johnston, R Woods, PR Elliott and PV Desmond have no conflicts of interest to declare. P De Cruz has received travel grant support from Abbvie and Schering-Plough. MA Kamm has acted as an advisor to Abbvie and Janssen, has received research support from Abbvie, and has acted as a speaker at symposiums sponsored by Abbvie and Janssen. A Hamilton has received an educational grant from Abbvie. D Liew has served on advisory boards and received research grants from Abbvie. IC Lawrance has been on an advisory board for Abbvie and Janssen, a speaker for Abbvie and Janssen, and has held research and travel grants from Abbvie and Janssen. JM Andrews has been an advisory board member for both Janssen and Abbvie, spoken for both Abbvie and Janssen, received research funds from both Abbvie and Janssen, and received travel grants from both Abbvie and Janssen. PA Bampton has been on advisory boards for Janssen and Abbvie, has received research funding from Abbvie, and travel sponsorship from both Abbvie and Janssen. MP Sparrow has been on the advisory board for Janssen and received speakers fees from Janssen and Abbvie. PR Gibson has received consulting fees from Abbvie, Janssen, and Schering-Plough; research support from Abbvie; and payments for lectures from Abbvie and Janssen. RB Gearry has been on an advisory board for Abbvie and Janssen, a speaker for Abbvie and Janssen, and held research, educational and travel grants from Abbvie and Janssen. FA Macrae has been on an advisory board to Janssen, has received travel grants from Abbvie, and has received clinical research support from Janssen, Abbvie and MSD. RW Leong has served on advisory boards for Abbvie and Janssen. G Radford-Smith has served on advisory boards for Abbvie and Janssen. W Selby has been on an advisory board for Abbvie. SJ Bell has received travel assistance from Abbvie. SJ Brown has received travel support and speaker fees from both Abbvie and Janssen. WR Connell has been on advisory board for Janssen and a speaker for Abbvie and Janssen.
